Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response-Reference-Cited by-同舟云学术

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

Published:2015-09 Issue:8 Volume:49 Page:675-682
ISSN:0192-0790
Container-title:Journal of Clinical Gastroenterology
language:en
Short-container-title:

Author:

Ma Christopher,Huang Vivian,Fedorak Darryl K.,Kroeker Karen I.,Dieleman Levinus A.,Halloran Brendan P.,Fedorak Richard N.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Reference4 articles.

1. Inflammatory bowel disease: cause and immunobiology.;Baumgart;Lancet,2007

2. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.;Trinder;J Gastroenterol Hepatol,2009

3. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.;Barreiro-de Acosta;World J Gastroenterol,2009

4. Adalimumab in ulcerative colitis: ready for prime time.;Danese;Dig Liver Dis,2013

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis;Cureus;2024-06-02

2. Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future;Future Pharmacology;2024-03-14

3. Intensified anti-TNF treatment downregulates the phenotype in ulcerative colitis: a 13-year prospective follow-up study;Frontiers in Gastroenterology;2024-01-24

4. RNA methylation in inflammatory bowel disease;Cancer Science;2024-01-23

5. Albumin change predicts failure in ulcerative colitis treated with adalimumab;PLOS ONE;2024-01-02